Drug Trial Radar · NCT07290985
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
242
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Jun 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- American Association for Cancer ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jazz Pharmaceuticals; BeOne Medicines; Astellas Pharma Inc; Natera, Inc.; Roche Diagnostics GmbH
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs based on each patient's tumor biomarkers. Upon enrollment onto the study, patients will consent to tumor biomarker testing and may receive one cycle of standard chemotherapy while awaiting results. Those with a matching biomarker will join the corresponding treatment group that combines chemotherapy, an immune checkpoint inhibitor, and/or a targeted therapy. In Stage I of the study, treatment lasts about four months before surgery, followed by an additional eight months of therapy for a total of one year. The most effective treatments from Stage I will be studied further in Stage II of the study to see whether some patients can safely avoid surgery. Those patients enrolled during Stage II will receive four months of the same combination treatment (chemotherapy, an immune checkpoint inhibitor, and/or a targeted therapy) but may be eligible to skip surgery if their cancer completely disappears after pre-surgery therapy. All patients will then receive an additional eight months of therapy and those who skipped surgery will be closely monitored with scans and endoscopies.
Conditions
- Gastroesophageal Adenocarcinoma
Interventions
TislelizumabDrug
150 mg every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively
LeucovorinDrug
400 mg/m² every 2 weeks for 4 months pre-operatively
OxaliplatinDrug
85 mg/m² every 2 weeks for 4 months pre-operatively
FluorouracilDrug
2,400 mg/m² every 2 weeks for 4 months pre-operatively
ZanidatamabDrug
1,200 mg for patients weighing less than 70 kg and 1,600 mg for patients weighing 70 kg or more every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively
ZolbetuximabDrug
A loading dose of 800mg/m2 zolbetuximab will be administered at cycle 1, followed by subsequent doses of 400 mg/m2 every 2 weeks for 4 months pre-operatively and up to 8 months post-operatively. In the postoperative maintenance therapy phase, dosing of 600 mg/m2 every 3 weeks may also be used
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pathCR) Rate (Stage I).Time frame: At time of surgery.
- Organ Preservation Rate (Stage II)Time frame: Up to 12 months post-treatment.
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.